1 – 53 of 53
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden : An observational cohort study
(
- Contribution to journal › Article
- 2022
-
Mark
20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation
(
- Contribution to journal › Article
-
Mark
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement : a study of the Chronic Malignancies Working Party of EBMT
(
- Contribution to journal › Article
- 2021
-
Mark
Development of acoustically isolated extracellular plasma vesicles for biomarker discovery in allogeneic hematopoietic stem cell transplantation
(
- Contribution to journal › Article
-
Mark
Organ sparing total marrow irradiation compared to total body irradiation prior to allogeneic stem cell transplantation
(
- Contribution to journal › Article
- 2020
-
Mark
Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis
(
- Contribution to journal › Scientific review
- 2019
-
Mark
Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML
(
- Contribution to journal › Article
-
Mark
Implementing safe and robust Total Marrow Irradiation using Helical Tomotherapy – A practical guide
(
- Contribution to journal › Article
-
Mark
Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting
(
- Contribution to journal › Article
-
Mark
High Graft-versus-Host Disease-Free, Relapse/Rejection-Free Survival and Similar Outcome of Related and Unrelated Allogeneic Stem Cell Transplantation for Aplastic Anemia : A Nationwide Swedish Cohort Study
(
- Contribution to journal › Article
- 2018
-
Mark
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
(
- Contribution to journal › Article
-
Mark
Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML : A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT)
(
- Contribution to journal › Article
-
Mark
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
(
- Contribution to journal › Article
-
Mark
Low response rate to ATG-based immunosuppressive therapy in very severe aplastic anaemia - A Swedish nationwide cohort study
(
- Contribution to journal › Article
-
Mark
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project
(
- Contribution to journal › Article
-
Mark
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma : Results from the collaboration to collect autologous transplant outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT chronic malignancies working party
(
- Contribution to journal › Article
- 2017
-
Mark
Incidence and outcome of acquired aplastic anemia : Real-world data from patients diagnosed in Sweden from 2000–2011
(
- Contribution to journal › Article
-
Mark
Long-term survival of patients with CLL after allogeneic transplantation : A report from the European Society for Blood and Marrow Transplantation
(
- Contribution to journal › Article
- 2016
-
Mark
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009
(
- Contribution to journal › Article
-
Mark
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
(
- Contribution to journal › Article
- 2015
-
Mark
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
(
- Contribution to journal › Article
-
Mark
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
(
- Contribution to journal › Article
-
Mark
Being a haematopoietic stem cell donor for a sick sibling: Adult donors' experiences prior to donation.
(
- Contribution to journal › Article
-
Mark
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
(
- Contribution to journal › Article
-
Mark
Outcome and risk factor analysis of molecular subgroups in cytogenetically normal AML treated by allogeneic transplantation.
(
- Contribution to journal › Article
-
Mark
Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation.
(
- Contribution to journal › Article
- 2014
-
Mark
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
(
- Contribution to journal › Article
-
Mark
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide
(
- Contribution to journal › Article
-
Mark
Having a sibling as donor: Patients' experiences immediately before allogeneic hematopoietic stem cell transplantation.
(
- Contribution to journal › Article
- 2013
-
Mark
Potential adult sibling stem cell donors' perceptions and opinions regarding an information and care model.
(
- Contribution to journal › Article
-
Mark
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
(
- Contribution to journal › Article
- 2012
-
Mark
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT
(
- Contribution to journal › Article
-
Mark
The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Factors associated with changes in quality of life in patients undergoing allogeneic haematopoietic stem cell transplantation.
2012) In European Journal of Cancer Care(
- Contribution to journal › Article
- 2011
-
Mark
Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party
(
- Contribution to journal › Article
- 2010
-
Mark
Multiparametric Flow Cytometry Profiling of Neoplastic Plasma Cells in Multiple Myeloma
(
- Contribution to journal › Article
-
Mark
Improved Survival for Multiple Myeloma in Denmark Based on Autologous Stem Cell Transplantation and Novel Drug Therapy in Collaborative Trials: Analysis of Accrual, Prognostic Variables, Selection Bias, and Clinical Behavior on Survival in More Than 1200 Patients in Trials of the Nordic Myeloma Study Group
(
- Contribution to journal › Article
-
Mark
Effective CD3 T-cell depletion using the CliniMacs (R) System to produce peripheral blood progenitor cell products for haploidentical transplantation in 23 children and adults: the updated Lund experience
2010) 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting In Bone Marrow Transplantation 45(Suppl.2). p.325-325(
- Contribution to journal › Published meeting abstract
-
Mark
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT
(
- Contribution to journal › Article
- 2009
-
Mark
Donor lymphocyte infusion as therapy for persistent pure red cell aplasia following major ABO-incompatible stem cell transplantation
2009) 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation In Bone Marrow Transplantation 43. p.373-373(
- Contribution to journal › Published meeting abstract
-
Mark
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
(
- Contribution to journal › Published meeting abstract
-
Mark
Impaired Stem Cell Mobilization by Fludarabine in MM: Results from a Randomized Phase II Trial
(
- Contribution to journal › Published meeting abstract
-
Mark
High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
(
- Contribution to journal › Article
- 2008
-
Mark
Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
(
- Contribution to journal › Article
- 2007
-
Mark
Serum calcium is an independent predictor of quality of life in multiple myeloma
(
- Contribution to journal › Article
- 2006
-
Mark
Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells
(
- Contribution to journal › Article
-
Mark
Quality assessment of autografting by probability evaluation: model estimation by clinical end-points in newly diagnosed multiple myeloma patients
(
- Contribution to journal › Article
-
Mark
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
(
- Contribution to journal › Article
- 2005
-
Mark
Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation
(
- Contribution to journal › Article
-
Mark
Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes
(
- Contribution to journal › Article
- 2004
-
Mark
Haematopoetic stem cell transplantation for refractory autoimmune cytopenia
(
- Contribution to journal › Article
-
Mark
Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma
(
- Contribution to journal › Article
- 1999
-
Mark
Granulopoietic growth factors. Cytokine and cellular regulation of GM-CSF and G-CSF production.
1999)(
- Thesis › Doctoral thesis (compilation)